ABLYNX ANNOUNCES WARRANTS EXERCISE AND CONVERSION OF BONDS
22 Gennaio 2018 - 7:00AM
YASTEST
REGULATED INFORMATION
GHENT, Belgium,
22 January 2018 - Ablynx [Euronext Brussels
and Nasdaq: ABLX] today announced, in conformity with Title II
of the Law of 2 May 2007 and the Royal Decree of 14 February 2008,
that an additional 218,998 new shares have been issued by the
Company in exchange for €1,689,981.62 as the result of the exercise
of warrants.
The Company also announced that in
relation to the €100,000,000, 3.25% Senior Unsecured Convertible
Bonds due on 27 May 2020 (ISIN: BE6278650344) issued by the Company
in the denomination of €100,000 each (the "Bonds"), an additional
126,348 new shares were issued following the conversion of 16
Bonds.
As a result of these transactions,
Ablynx now has a share capital of €140,320,046.59 represented by a
total number of 75,065,990 shares, conferring a total number of
75,065,990 voting rights.
The current total number of
outstanding rights (warrants) to subscribe for not yet issued
securities conferring voting rights is 2,667,506, entitling their
holders to subscribe for a total number of 2,667,506 new shares,
conferring a total number of 2,667,506 voting rights.
The current total number of
outstanding convertible bonds is 984, which, on the basis of the
current conversion price of €12.6631, are convertible into
7,770,609 new shares, conferring a total number of 7,770,609 voting
rights.
About
Ablynx
Ablynx is a biopharmaceutical
company engaged in the development of Nanobodies®, proprietary
therapeutic proteins based on single-domain antibody fragments,
which combine the advantages of conventional antibody drugs with
some of the features of small-molecule drugs. Ablynx is dedicated
to creating new medicines which will make a real difference to
society. Today, the Company has more than 45 proprietary and
partnered programmes in development in various therapeutic areas
including inflammation, haematology, immuno-oncology, oncology and
respiratory disease. The Company has collaborations with multiple
pharmaceutical companies including AbbVie; Boehringer Ingelheim;
Eddingpharm; Merck & Co., Inc., Kenilworth, New Jersey, USA;
Merck KGaA; Novartis; Novo Nordisk; Sanofi and Taisho
Pharmaceuticals. The Company is headquartered in Ghent, Belgium.
More information can be found on www.ablynx.com.
For more
information, please contact
Ablynx:
Dr Edwin Moses
CEO
t: +32 (0)9 262 00 07
m: +32 (0)473 39 50 68
e: edwin.moses@ablynx.com
Lies Vanneste
Director Investor Relations
t: +32 (0)9 262 01 37
m: +32 (0)498 05 35 79
e: lies.vanneste@ablynx.com
Follow us on Twitter @AblynxABLX
Ablynx media
relations:
Consilium Strategic Communications
Mary-Jane Elliott, Philippa Gardner, Sukaina Virji
t: +44 (0)20 3709 5700
e: ablynx@consilium-comms.com
Joele Frank,
Wilkinson Brimmer Katcher
Dan Katcher or Joseph Sala
t: +1 212-355-4449
pdf version of the press
release
This
announcement is distributed by Nasdaq Corporate Solutions on behalf
of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: Ablynx via Globenewswire
Grafico Azioni Ablynx NV (NASDAQ:ABLX)
Storico
Da Ago 2024 a Set 2024
Grafico Azioni Ablynx NV (NASDAQ:ABLX)
Storico
Da Set 2023 a Set 2024